Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy
Melissa Krystel‐Whittemore, Jin Xu, Edi Brogi et al. · Breast Cancer Research and Treatment · 2019
Cited by 80 works. doi:10.1007/s10549-019-05295-9
Authors
- Melissa Krystel‐Whittemore
- Jin Xu
- Edi Brogi
- Katia Ventura
- Sujata N Patil
- Dara S. Ross
- Chau T. Dang
- Mark E. Robson
- Larry Norton
- Monica Morrow
- Hannah Yong Wen
References
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer
- Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
- US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)